Announcement, Our Impact 09.07.22 Share on Twitter Share on Facebook Share on LinkedIn PICI Network Researchers to Present at ESMO Congress 2022 #ESMO22 Parker Institute for Cancer Immunotherapy (PICI) Network investigators will be among other leading researchers presenting the latest advances in cancer treatment at ESMO Congress 2022, Sept. 9-13 in Paris and online. Hosted by the European Society for Medical Oncology, the conference includes presentations by six PICI Network members from four PICI-affiliated institutions: Eileen O’Reilly, MD; Geoffrey Y. Ku, MD; and Claire F. Friedman, MD, all of Memorial Sloan Kettering Cancer Center Adil Daud, MD, of the University of California, San Francisco Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center Elizabeth Mittendorf, MD, PhD, of Dana-Farber Cancer Institute Below are the sessions featuring PICI investigators. Please note that all events listed are subject to change. For the most current information, visit the ESMO Congress program. Follow the meeting live on Twitter using the hashtag #ESMO22. Sept. 9 Special Symposium: Lessons Learned and New Horizons and Other Hepatobiliary/Pancreatic Malignancies 10:15-11:45 a.m. Central European Summer Time (CEST) Speaker: Eileen O’Reilly, MD (Twitter: @EileenMOReilly) Topic: The Role of KRAS Inhibitor and Other New Treatment Options in Pancreatic Cancer 11:05-11:20 a.m. CEST Special Symposium: How the Tumor Microenvironment Affects Outcome and Therapy Response Chair and Speaker: Adil Daud, MD (Twitter: @ad1600) 2-3:30 p.m. CEST Topic: Organ-specific Tumor Microenvironment, 2:10-2:25 p.m. CEST Conclusions and Perspectives, 2:55-3 p.m. CEST Sept. 10 Special Symposium: Progress in the Identification of New Immune Targets 8:30-10 a.m. CEST Speaker: Padmanee Sharma, MD, PhD (Twitter: @PamSharmaMDPhD) Topic: Novel Immune Checkpoints, 8:40-8:55 a.m. CEST Mini Oral Session: GI, Upper Digestive 2:45-4:15 p.m. CEST Speaker: Geoffrey Y. Ku, MD Topic: Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen Presentation Number: 1205MO 3:45-3:50 p.m. CEST Sept. 11 Proffered Paper Session: Basic Science & Translational Research 4:30-6 p.m. CEST Speaker: Claire F. Friedman, MD (Twitter: @ClaireFriedma19) Topic: MyPathway: A Multiple Target, Multiple Basket Study of Targeted Treatments in Tissue-agnostic Cohorts of Patients with Advanced Solid Tumors Presentation Number: 66O 4:50-5 p.m. CEST Sept. 12 Multidisciplinary Session: Oligometastatic Disease and Oligoprogression in Breast Cancer 3-4 p.m. CEST Speaker: Elizabeth Mittendorf, MD, PhD (Twitter: @EMittendorfMD) Topic: Surgery 3:20-3:35 p.m. CEST Related Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024 Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research
Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy